Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Neoplasm, Residual

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplastic Processes

Both primary tumor and nodal response achieve major pathological response (MPR).

Primary tumor or/and nodal response can not achieve MPR.

The effect of drug administration timing on tumor and lymph node responses was observed.

Timing of drug administration

Guibin Qiao, MD

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Real-world Analysis of Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable Non-small Cell Lung Cancer

the time from diagnosis to any progression of disease precluding surgery, progression or recurrence of disease after surgery or death from any cause.

Guangdong Provincial People's Hospital

Nervous System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Glioma

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Neuroepithelial

Dermatitis, Phototoxic

Dermatitis

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Brain Diseases

Central Nervous System Diseases

Dermatitis, Irritant

Dermatitis, Contact

Skin Diseases

Photosensitivity Disorders

Skin Diseases, Eczematous

Neuroepithelioma

Central Nervous System Depressants

All Drugs and Chemicals

Pharmaceutical Solutions

Dermatologic Agents

Anesthetics

Aminolevulinic Acid

Photosensitizing Agents

Patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy

Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.

5-Aminolevulinic Acid (5-ALA) Gliolan®

During the surgical exploration of the glioma, the neurosurgeon will attempt to identify the mass. The location of the tumor will be assessed using the blue-light filtered microscope. A biopsy of the fluorescent region will be taken to confirm the glioma subtype. The tumor will then be maximally resected.

Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)

Alberto Valarezo Chuchuca, MD

The goal of this observational study is to evaluate disease-free survival (DFS) in patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy

The investigators are proposing a study that provides descriptive understanding of patients with High-Grade Gliomas in Ecuador. The primary objective of this pilot study is to lay the foundations for the development of a multicenter registry patients with malignant gliomas undergoing neurosurgical procedures using 5-aminolevulinic acid (5-ALA)-based photodynamic therapy, which will provide high-quality real data and serve as a basis for the application to future projects and elaboration of public policies in the medium and long term.

5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas

Disease-Free-Survival calculates the time from treatment until the recurrence of disease or death after undergoing Fluorescence-Guided Surgery using 5-aminolevulinic acid (5-ALA)

Overall survival is defined as time from initiation to death of any cause

The questionnaire provides an additional set of disease-specific questions pertaining to brain neoplasms. It consists of 46 items that refer to general issues of quality of life and specific to tumor location. Possible scores range from 0 to 108, with higher scores indicating better quality of life.

The average length of stay in hospitals is often used as an indicator of efficiency. The ALOS refers to the average number of days that patients spend in hospital after surgery. It is calculated by dividing the number of bed-days by the number of discharges after procedure. Average length of stay range from 1 day to 4.5 days. Longer than average stays are usually a symptom of poor communication, quality of care, and effectiveness of treatment.

Sociedad de Lucha Contra el Cáncer del Ecuador

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC	NCT05637580	Non Small Cell ... Immunotherapy Chemotherapy Tumour, Residua...	Timing of drug ...	18 Years -	Guangdong Provincial People's Hospital
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas	NCT05850377	High Grade Glio... Glioma Glioma, Maligna... Neoplasms, Neur... Neuroectodermal... Photosensitizin... Neoplasm Malign... Brain Neoplasms... Central Nervous... Brain Tumor Tumour, Residua...	5-Aminolevulini... Fluorescence-Gu...	18 Years - 75 Years	Sociedad de Lucha Contra el Cáncer del Ecuador
Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC	NCT05637580	Non Small Cell ... Immunotherapy Chemotherapy Tumour, Residua...	Timing of drug ...	18 Years -	Guangdong Provincial People's Hospital

Spots Global Cancer Trial Database for tumour, residual